Appearance: White crystalline powder； Solubility: Slightly soluble in water, slightly soluble in ethanol. Related substances: The sum of peak areas of each impurity shall not exceed the main peak area of the reference solution (1.0%). Dry weight loss: not exceeding 0.5%； Burning residue: not exceeding 0.1%； Heavy metals: not exceeding 20ppm； Content: not less than 98.5%；
Pharmacological effects:
This product is a novel non anesthetic analgesic with mild antipyretic and muscle relaxant effects. The chemical structure belongs to cyclized ortho methyldiphenhydramine. So it does not have the characteristics of nonsteroidal anti-inflammatory drugs, nor is it an opioid receptor agonist. Effective for moderate to severe pain, intramuscular injection of 20mg of this product is equivalent to the effect of 12mg of morphine. The respiratory inhibitory effect is relatively mild. Has no inhibitory effect on the circulatory system. Lack of tolerance and dependence. Acute toxicity LD50 (mg/kg): Mice, oral administration 66.6; Abdominal cavity 28.7; Vein 21.9. Rats, orally administered 178; Intramuscular injection 56.9.
Appearance: White or off white crystalline powder; Solubility: This product is easily soluble in methanol, ethanol, acetone, glacial acetic acid, and dilute ethanol, soluble in chloroform, slightly soluble in water, and almost insoluble in ether. Melting point: should be 88.5~93.5 ℃; Acidity: The pH value should be 5.5~7.0; Sulfate: not exceeding 0.01%; Moisture content: not exceeding 0.5%; Burning residue: not exceeding 0.1%; Heavy metals: not exceeding 20 parts per million; Related substances: Single impurities shall not exceed 0.1%; The total impurities shall not exceed 0.20%; Content: should be between 99.0% and 101.0%.
Indications: Suitable for the treatment of coronary heart disease and angina pectoris. Effective for exertional, spontaneous, post infarction, or mixed angina pectoris. For patients with angina pectoris accompanied by atrial fibrillation and cardiac enlargement, and for patients who need to use other anti angina drugs with caution.
Appearance: This product is a crystalline powder ranging from off white to light yellow in color; Solubility: It should be slightly soluble in N, N-dimethylformamide and minimally soluble in water or ethanol; Easy to dissolve in acetic acid, hydrochloric acid or sodium hydroxide solution; Melting point: 218~224 ° C; Clarity of the solution: Compared with the turbidity standard solution No. 2, it should not be more concentrated. Regarding substances: Impurity A should not exceed 0.2%, individual impurities should not exceed 0.1%, and total impurities should not exceed 0.5%; Dry weight loss: not exceeding 1.0%; Burning residue: not exceeding 0.1%; Heavy metals: not exceeding 15ppm; Content: should be 98.5-102.0%.
Appearance: Crystalline powder ranging from off white to slightly yellow green in color; Melting point: 198-202 ℃, melting and decomposing simultaneously. Regarding substances: The maximum single impurity shall not exceed 0.1%; The total magazine shall not exceed 1.0%; Chloride: not exceeding 0.1%; Dry weight loss: not exceeding 1.0%; Burning residue: not exceeding 0.1%; Heavy metals: not exceeding 20ppm; Arsenic salt: not exceeding 0.0004% Content: not less than 98.5%.
Indications: To provide symptomatic treatment for relieving pain and swelling in various types of arthritis and soft tissue lesions.
Appearance: White crystals or colorless crystalline powder; Acidity pH: 5.0-6.5; Solution appearance: Solution S is clear and colorless; Sulfuric acid ash content: not exceeding 0.1%; Dry weight loss: not exceeding 0.5%; Related substances: not exceeding 0.05%; Aminobenzoic acid: not exceeding 0.5%; Iron salt: not exceeding 0.001%; Heavy metals: not exceeding 5PPM; Content: should be between 99.0% and 101.0%.
Appearance: This product is a white to slightly yellow powder or crystalline powder; Odorless. Melting point: The melting point of this product is 148.5~152.0 ℃. Chloride: not exceeding 0.005%. Dry weight loss: not exceeding 0.5%. Burning residue: not exceeding 0.1%. Heavy metals: not exceeding 10ppm. Regarding substances: maximum single impurity ≤ 0.5%, total impurity ≤ 0.5%. Content: not less than 99.0%.
Appearance: White or off white crystalline powder Melting point: 153~158 ℃ PH value: 3.5~5.5 Regarding substances: individual impurities should not exceed 0.10%, and total impurities should not exceed 1.0%; Dry weight loss: not exceeding 0.5%; Burning residue: not exceeding 0.1%; Heavy metals: not exceeding 20 parts per million; Optical isomers: not exceeding 1.0%; Content: should be between 98.5% and 101.0%.
Indications: monotherapy (not in combination with levodopa) for idiopathic Parkinson’s disease or adjuvant therapy (in combination with levodopa) for Parkinson’s disease with dose fluctuations.
Solubility：Practically insoluble in water, freely soluble in methylene chloride, sparingly soluble in ethanol (96 per cent). It dissolves in dilute acid solutions.
Appearance of solution：The solution is clear and colourless.
Related substances：
Impurity A ,B,C,D,E ≤ 0.2 % ;Impurity K ≤ 0.15 % ;unspecified impurities≤ 0.10 % ;total≤ 0.3%;
Loss on drying：Maximum 0.5 percent
Sulfated ash：Maximum 0.1 percent
Assay：99.0 per cent to 101.0% per cent（dried substance).
Used for treating acute and chronic schizophrenia. Especially for positive and negative symptoms and their accompanying emotional symptoms (such as anxiety, depression, etc.), it has good therapeutic effects. It can also alleviate emotional symptoms associated with schizophrenia. For patients who are effectively treated in the acute phase, this product can continue to exert its clinical efficacy during maintenance treatment.
Solubility: soluble in chloroform, DMSO (87 mg/ml, 25 ℃), water (<1 mg/ml, 25 ℃), and ethanol (<1 mg/ml, 25 ℃).
Melting Point：228-229°C
Specific rotation: -38 to -42 °
Content: 99%
Usage: Rivaroxaban is a highly selective oral medication that directly inhibits factor Xa. Inhibition of factor Xa can interrupt the endogenous and exogenous pathways of coagulation cascade, inhibiting the production of thrombin and thrombus formation. Rivaroxaban does not inhibit thrombin (activating factor II), nor has it been proven to have an effect on platelets. Rivaroxaban is used in adult patients undergoing elective hip or knee replacement surgery to prevent venous thrombosis (VTE).
Appearance: White to off white or light yellow powder; It smells bad. Solubility: This product is highly soluble in anhydrous ethanol, acetonitrile, and 0.1mol/L hydrochloric acid solution, soluble in water and N, N-dimethylformamide, and almost insoluble in ether. Specific rotation: from+28.5 ° to+32.0 °; The clarity of the solution should not exceed the turbidity of standard solution No.1; The color of the solution should not be darker than the yellow standard colorimetric solution No. 2; Alkalinity: The pH value should be between 8.9 and 9.5 Moisture content: not exceeding 3.0% Burning residue: not exceeding 0.1% Heavy metals: not exceeding 10 parts per million Regarding substances: Impurity A shall not exceed 0.2%, Impurity B shall not exceed 0.3%, other impurities shall not exceed 0.1%, and total impurities shall not exceed 1.0%; Content: should be between 99.0% and 101.0%.
Indications: As an adjuvant for general anesthesia, perform routine endotracheal intubation and relax skeletal muscles during surgery or mechanical breathing to facilitate surgical operations and improve gas exchange in the body. Suitable for general anesthesia, relaxing skeletal muscles, and endotracheal intubation.
